Abstract
Primary glandular bladder tumours (bladder adenocarcinoma [BAC], urachal adenocarcinoma [UAC], urothelial carcinoma with glandular differentiation [UCg]) are rare malignancies with histological resemblance to colorectal adenocarcinoma (CORAD) in the majority of this subgroup. Definite case numbers are very low, molecular data are limited and the pathogenesis remains poorly understood. Therefore, this study was designed to complement current knowledge by in depth analysis of BAC (n = 12), UAC (n = 13), UCg (n = 11) and non-invasive glandular lesions (n = 19). In BAC, in addition to known alterations in TP53, Wnt, MAP kinase and MTOR pathway, mutations in SMAD4, ARID1A and BRAF were identified. Compared to published data on muscle invasive bladder cancer (BLCA) and CORAD, UCg exhibited frequent “urothelial” like alterations while BAC and UAC were characterised by a more “colorectal” like mutational pattern. Immunohistochemically, there was no evidence of DNA mismatch repair deficiency or PD-L1 tumour cell positivity in any sample. Depending on the used antibody 0–45% of BAC, 0–30% of UCg and 0% UAC cases exhibited PD-L1 expressing tumour associated immune cells. A single BAC (9%, 1/11) showed evidence of ARID1A protein loss, and two cases of UCg (20%, 2/10) showed loss of SMARCA1 and PBRM1, respectively. Taken together, our data suggest at least in part involvement of similar pathways driving tumourigenesis of adenocarcinomas like BAC, UAC and CORAD independent of their tissue origin. Alterations of TERT and FBXW7 in single cases of intestinal metaplasia further point towards a possible precancerous character in line with previous reports.
Highlights
Materials and methodsPrimary adenocarcinoma of the bladder is a rare malignancy accounting for < 2% of all bladder cancers [1]
SMAD4 was altered in bladder adenocarcinoma (BAC) (33%, 4/12) and urachal adenocarcinomas (UAC) (23%, 3/13), but not in any of the UCg samples
TERT promoter mutations were present in 64% (7/11) of UCg cases but only in two (17%, 2/12) BAC cases and no UAC sample (0/13)
Summary
Materials and methodsPrimary adenocarcinoma of the bladder is a rare malignancy accounting for < 2% of all bladder cancers [1]. The aim of our study was to decipher genomic similarities and differences in glandular bladder tumours (BAC, UAC and UCg) in comparison to publicly available data on muscle invasive urothelial cancers (BLCA) and CORAD using a custom NGS panel covering all exons of 20 urothelial and colorectal driver genes in order to understand tumour biology and reveal suitable (targeted) therapeutic concepts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.